7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver diseaseActive, not recruitingPhase 32026-09-04NCT04822181
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vesselscardiovascular disorderActive, not recruitingPhase 32026-08-31NCT05669755
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinosarcoma, fallopian tube endometrioid adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian carcinosarcoma, ovarian disorderRecruitingPhase 32026-08-07NCT06580314
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®Bone Diseases, Developmental, Bone Diseases, Endocrine, Dwarfism, bone disorder, brain disorder, central nervous system disorder, endocrine system disorder, hypopituitarism, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, pituitary dwarfism, pituitary gland disorderActive, not recruitingNot stated2026-04-13NCT05230550
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingNot applicable2026-02-09NCT02308085
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseBrain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fabry disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis, vascular disorderActive, not recruitingPhase 32026-02-04NCT05206773
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerAdnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, connective tissue neoplasm, cystic, mucinous, and serous neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, mucinous adenocarcinoma, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian clear cell malignant adenofibroma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated carcinoma, undifferentiated ovarian carcinomaActive, not recruitingPhase 32025-12-30NCT00565851